Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Audenz (aH5N1c) in Healthy Elderly
NCT01766921Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2013
- Primary completion
- Jul 2013
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 4
01
Overview
A Phase 2 trial of MF59-eH5N1, sponsored by Novartis. Started Jan 2013; status: completed.
02
Drugs
MF59-eH5N1
Beyond the preview
Go deeper on NCT01766921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01766921.